Pértille F, Rezaei S, Uffenorde J, Gimm O, Hosseinpour Feizi MA, Coutinho LL, Guerrero-Bosagna C
FEBS Open Bio - (-) - [2026-11-09; online 2026-11-09]
Tumor development arises from combined genetic and epigenetic alterations, yet most sequencing approaches examine these layers independently. We present GBS-MeDIP, a low-input and cost-efficient method that combines genotype-by-sequencing with methylated DNA immunoprecipitation to jointly identify single nucleotide polymorphisms (SNPs), copy number variations (CNVs), and differentially methylated regions (DMRs) within the same genomic fraction. The method was evaluated in two clinical contexts: gastric adenocarcinoma (a malignant epithelial tumor) and parathyroid adenoma (a benign endocrine tumor). In both case studies, we detected thousands of SNPs, with principal component analysis (PCA) revealing genetic divergence in gastric tumors and substantial inter-individual genetic background differences in parathyroid samples. We identified many CNVs in both datasets, with CNVs more frequent in parathyroid tumors, showing a stronger representation in promoter regions than SNPs. Gastric cancer showed a balanced methylation profile, with four DMRs reaching false discovery rate (FDR) significance, whereas Mimpara-treated parathyroid tumors displayed widespread hypermethylation, with all significant DMRs hypermethylated. These significant DMRs mapped to genes involved in immune regulation, chromatin function, DNA repair, and endocrine signaling. Annotation analysis demonstrated that, in both tissues, CNVs were enriched in promoter and exonic regions, whereas DMRs were preferentially located in intronic and intergenic regions, reflecting the CpG-enriched reduced genomic fraction accessed by GBS-MeDIP. Importantly, both datasets contained DMRs overlapping CNVs, highlighting the method's ability to reveal genetic confounders in methylation studies. Together, these results show that GBS-MeDIP enables combined genomic and epigenomic profiling in heterogeneous clinical tumor samples.
NGI Uppsala (SNP&SEQ Technology Platform) [Service]
National Genomics Infrastructure [Service]
PubMed 43004876
DOI 10.1002/2211-5463.70360
Crossref 10.1002/2211-5463.70360